Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin. (1st July 2020)

• Record Type: Journal Article
• Authors: Sexe, Jordan; Mayes, Chadwick; Tofts, Peter
• Other Names: Molnár Zsolt Academic Editor.
• Is Part Of: Case reports in critical care. Volume 2020(2020)
• Publication Date: 2020-07-01
• Subjects: Critical care medicine -- Periodicals; Emergency medicine -- Periodicals; Medical emergencies -- Periodicals; 616.02805
• DOI: 10.1155/2020/7437892
• Languages: English
• ISSNs: 2090-6420

Abstract

Abstract : Diabetic ketoacidosis is a leading cause of morbidity and mortality in diabetic patients, and its diagnosis should be timely and accurate. SGLT2 inhibitors are a new class of antidiabetic medications that increase the renal excretion of glucose. It is thought that increased urinary excretion of glucose will mask hyperglycemia during DKA. This can lead to a delayed diagnosis of DKA and worsen outcomes. In this report, we detail a case of euglycemic DKA in a patient who presented to the Emergency Department meeting criteria for septic shock.